[
  {
    "ts": null,
    "headline": "U.S. Food and Drug Administration Approves Opdivo速 (nivolumab) plus Yervoy速 (ipilimumab) as a Treatment for Patients with Previously Untreated Microsatellite Instability-High or Mismatch Repair Deficient Unresectable or Metastatic Colorectal Cancer1",
    "summary": "PRINCETON, N.J., April 08, 2025--US FDA Approves Opdivo plus Yervoy as a Treatment for Patients with Previously Untreated Microsatellite Instability-High or Mismatch Repair...",
    "url": "https://finnhub.io/api/news?id=5663662e50cdeee55491105e64144ba9af688674bad0bcc29133a66546eee497",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744140960,
      "headline": "U.S. Food and Drug Administration Approves Opdivo速 (nivolumab) plus Yervoy速 (ipilimumab) as a Treatment for Patients with Previously Untreated Microsatellite Instability-High or Mismatch Repair Deficient Unresectable or Metastatic Colorectal Cancer1",
      "id": 133823755,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "PRINCETON, N.J., April 08, 2025--US FDA Approves Opdivo plus Yervoy as a Treatment for Patients with Previously Untreated Microsatellite Instability-High or Mismatch Repair...",
      "url": "https://finnhub.io/api/news?id=5663662e50cdeee55491105e64144ba9af688674bad0bcc29133a66546eee497"
    }
  },
  {
    "ts": null,
    "headline": "Artiva Biotherapeutics Names New Chief Medical Officer",
    "summary": "Artiva Biotherapeutics Names New Chief Medical Officer",
    "url": "https://finnhub.io/api/news?id=a312721fde8986d8784352684610d3404e8f831649ff931ec2b7642baf809a4a",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744131420,
      "headline": "Artiva Biotherapeutics Names New Chief Medical Officer",
      "id": 133833123,
      "image": "",
      "related": "BMY",
      "source": "MarketWatch",
      "summary": "Artiva Biotherapeutics Names New Chief Medical Officer",
      "url": "https://finnhub.io/api/news?id=a312721fde8986d8784352684610d3404e8f831649ff931ec2b7642baf809a4a"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb Co. stock underperforms Tuesday when compared to competitors",
    "summary": "Bristol Myers Squibb Co. stock underperforms Tuesday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=178d51254d24ed9dfab26c8ff29a8c33b2ab3206f61a6cbca5edd38da27ae3f4",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744130220,
      "headline": "Bristol Myers Squibb Co. stock underperforms Tuesday when compared to competitors",
      "id": 133833125,
      "image": "",
      "related": "BMY",
      "source": "MarketWatch",
      "summary": "Bristol Myers Squibb Co. stock underperforms Tuesday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=178d51254d24ed9dfab26c8ff29a8c33b2ab3206f61a6cbca5edd38da27ae3f4"
    }
  },
  {
    "ts": null,
    "headline": "Goldman turns cautious on major pharma names, sees select upside at Eli Lilly",
    "summary": "Investing.com -- Goldman Sachs initiated coverage on several large-cap pharmaceutical companies, taking a cautious stance on Bristol-Myers Squibb (NYSE:BMY), Pfizer (NYSE:PFE), and AbbVie (NYSE:ABBV), while upgrading Eli Lilly (NYSE:LLY) to a Buy on strong growth prospects in obesity treatments.",
    "url": "https://finnhub.io/api/news?id=79226bcb7596285f28ccfc803c594c16b98e3dc7715b9d1f3c7d0d9b11ba1be3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744117697,
      "headline": "Goldman turns cautious on major pharma names, sees select upside at Eli Lilly",
      "id": 133820740,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Investing.com -- Goldman Sachs initiated coverage on several large-cap pharmaceutical companies, taking a cautious stance on Bristol-Myers Squibb (NYSE:BMY), Pfizer (NYSE:PFE), and AbbVie (NYSE:ABBV), while upgrading Eli Lilly (NYSE:LLY) to a Buy on strong growth prospects in obesity treatments.",
      "url": "https://finnhub.io/api/news?id=79226bcb7596285f28ccfc803c594c16b98e3dc7715b9d1f3c7d0d9b11ba1be3"
    }
  }
]